- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Patent holdings for IPC class C07D 401/14
Total number of patents in this class: 18746
10-year publication summary
1214
|
1236
|
1220
|
1439
|
1475
|
1506
|
1499
|
1680
|
1447
|
826
|
2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
Owner |
All patents
|
This class
|
---|---|---|
Bristol-myers Squibb Company | 4898 |
442 |
Novartis AG | 10849 |
357 |
Boehringer Ingelheim International GmbH | 4650 |
341 |
Merck Sharp & Dohme LLC | 3748 |
280 |
Gilead Sciences, Inc. | 2036 |
266 |
F. Hoffmann-La Roche AG | 7925 |
244 |
Janssen Pharmaceutica N.V. | 3392 |
235 |
Takeda Pharmaceutical Company Limited | 2713 |
228 |
Merck Patent GmbH | 5831 |
209 |
Pfizer Inc. | 3387 |
193 |
Amgen Inc. | 4074 |
178 |
Dana-Farber Cancer Institute, Inc. | 2571 |
175 |
AstraZeneca AB | 2909 |
162 |
Hoffmann-La Roche Inc. | 3418 |
150 |
Genentech, Inc. | 3976 |
148 |
Vertex Pharmaceuticals Incorporated | 1597 |
134 |
Rigel Pharmaceuticals, Inc. | 539 |
125 |
Syngenta Crop Protection AG | 6054 |
109 |
LG Chem, Ltd. | 17632 |
106 |
Celgene Corporation | 1401 |
100 |
Other owners | 14564 |